These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34264886)

  • 21. A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†.
    Reiman T; Savage KJ; Crump M; Cheung MC; MacDonald D; Buckstein R; Couban S; Piliotis E; Imrie K; Spaner D; Shivakumar S; Kuruvilla J; Villa D; Shepherd LE; Skamene T; Winch C; Chen BE; Hay AE
    Leuk Lymphoma; 2019 Apr; 60(4):912-919. PubMed ID: 30301414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials.
    Shustov A; Coiffier B; Horwitz S; Sokol L; Pro B; Wolfson J; Balser B; Eisch R; Popplewell L; Prince HM; Allen SL; Piekarz R; Bates S
    Leuk Lymphoma; 2017 Oct; 58(10):2335-2341. PubMed ID: 28264616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Romidepsin (Istodax
    Ro T; Nakayama N; Achiwa H; Ohtsu T
    Nihon Yakurigaku Zasshi; 2018; 151(3):122-129. PubMed ID: 29526921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.
    Piekarz RL; Frye R; Prince HM; Kirschbaum MH; Zain J; Allen SL; Jaffe ES; Ling A; Turner M; Peer CJ; Figg WD; Steinberg SM; Smith S; Joske D; Lewis I; Hutchins L; Craig M; Fojo AT; Wright JJ; Bates SE
    Blood; 2011 Jun; 117(22):5827-34. PubMed ID: 21355097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
    Strati P; Chihara D; Oki Y; Fayad LE; Fowler N; Nastoupil L; Romaguera JE; Samaniego F; Garg N; Feng L; Wesson ET; Ruben CE; Stafford MD; Nieto Y; Khouri IF; Hosing C; Horowitz SB; Kamble RT; Fanale MA
    Haematologica; 2018 Sep; 103(9):e416-e418. PubMed ID: 29622656
    [No Abstract]   [Full Text] [Related]  

  • 26. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
    Amengual JE; Lichtenstein R; Lue J; Sawas A; Deng C; Lichtenstein E; Khan K; Atkins L; Rada A; Kim HA; Chiuzan C; Kalac M; Marchi E; Falchi L; Francescone MA; Schwartz L; Cremers S; O'Connor OA
    Blood; 2018 Jan; 131(4):397-407. PubMed ID: 29141948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma.
    Kalac M; Jain S; Tam CS; Xiao Z; Montanari F; Kanakry J; Huber BD; Goldfinger M; O'Connor OA; Marchi E
    Blood Adv; 2023 Jul; 7(14):3760-3763. PubMed ID: 36790924
    [No Abstract]   [Full Text] [Related]  

  • 28. Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement.
    Chan KL; van der Weyden C; Khoo C; Lade S; Blombery P; Westerman D; Khot A; Melo B; Johnstone RW; Prince HM; Dickinson M
    Leuk Lymphoma; 2017 Apr; 58(4):996-998. PubMed ID: 27558082
    [No Abstract]   [Full Text] [Related]  

  • 29. Novel agents in development for peripheral T-cell lymphoma.
    O'Connor OA
    Semin Hematol; 2010 Apr; 47 Suppl 1():S11-4. PubMed ID: 20359580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Romidepsin-Bendamustine Combination for Relapsed/Refractory T Cell Lymphoma.
    Nachmias B; Shaulov A; Lavie D; Goldschmidt N; Gural A; Saban R; Lebel E; Gatt ME
    Acta Haematol; 2019; 141(4):216-221. PubMed ID: 30943470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.
    Woo S; Gardner ER; Chen X; Ockers SB; Baum CE; Sissung TM; Price DK; Frye R; Piekarz RL; Bates SE; Figg WD
    Clin Cancer Res; 2009 Feb; 15(4):1496-503. PubMed ID: 19228751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas.
    Strati P; Nastoupil LJ; Davis RE; Fayad LE; Fowler N; Hagemeister FB; Kwak L; Oki Y; Wang M; Westin J; Ruben CE; Wesson ET; Piekarz R; Fanale MA; Lee HJ
    Haematologica; 2020 Jan; 105(1):e26-e28. PubMed ID: 31073068
    [No Abstract]   [Full Text] [Related]  

  • 33. Complete remission with romidepsin in a patient with T-cell acute lymphoblastic leukemia refractory to induction hyper-CVAD.
    Brunvand MW; Carson J
    Hematol Oncol; 2018 Feb; 36(1):340-343. PubMed ID: 28560733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma.
    Puig N; Wang L; Seshadri T; al-Farsi K; Keating A; Crump M; Kuruvilla J
    Leuk Lymphoma; 2013 Mar; 54(3):507-13. PubMed ID: 22897731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Romidepsin for peripheral T-cell lymphoma.
    Khot A; Dickinson M; Prince HM
    Expert Rev Hematol; 2013 Aug; 6(4):351-9. PubMed ID: 23991922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The discovery and development of romidepsin for the treatment of T-cell lymphoma.
    Smolewski P; Robak T
    Expert Opin Drug Discov; 2017 Aug; 12(8):859-873. PubMed ID: 28641053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
    Shi Y; Jia B; Xu W; Li W; Liu T; Liu P; Zhao W; Zhang H; Sun X; Yang H; Zhang X; Jin J; Jin Z; Li Z; Qiu L; Dong M; Huang X; Luo Y; Wang X; Wang X; Wu J; Xu J; Yi P; Zhou J; He H; Liu L; Shen J; Tang X; Wang J; Yang J; Zeng Q; Zhang Z; Cai Z; Chen X; Ding K; Hou M; Huang H; Li X; Liang R; Liu Q; Song Y; Su H; Gao Y; Liu L; Luo J; Su L; Sun Z; Tan H; Wang H; Wang J; Wang S; Zhang H; Zhang X; Zhou D; Bai O; Wu G; Zhang L; Zhang Y
    J Hematol Oncol; 2017 Mar; 10(1):69. PubMed ID: 28298231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modified ESHAP regimen for relapsed/refractory T cell lymphoma: a retrospective analysis.
    Kogure Y; Yoshimi A; Ueda K; Nannya Y; Ichikawa M; Nakamura F; Kurokawa M
    Ann Hematol; 2015 Jun; 94(6):989-94. PubMed ID: 25687839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?
    Lunning MA; Horwitz S
    Curr Treat Options Oncol; 2013 Jun; 14(2):212-23. PubMed ID: 23568456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma.
    Bates SE; Zhan Z; Steadman K; Obrzut T; Luchenko V; Frye R; Robey RW; Turner M; Gardner ER; Figg WD; Steinberg SM; Ling A; Fojo T; To KW; Piekarz RL
    Br J Haematol; 2010 Jan; 148(2):256-67. PubMed ID: 19874311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.